Product category:
Laboratory and scientific professional organisations
News Release from: Cancer Research UK
Edited by the Laboratorytalk Editorial
Team on 07 December 2004
Licence to tackle nuclear receptors
Cancer Research Technology grants AstraZeneca an exclusive licence to a key patent in the field of nuclear receptors
Cancer Research Technology has announced that AstraZeneca has licensed exclusive worldwide rights to a patent family relating to a nuclear receptor/co-activator binding motif Nuclear receptors require co-activator binding in order to activate gene transcription
This article was originally published on Laboratorytalk on 10 Dec 2003 at 8.00am (UK)
Related stories
New test could prevent more cervical cancer
A new test could be a more effective early warning system for preventing cervical cancer than the traditional smear according to Cancer Research UK scientists
Ligand-induced nuclear receptor conformational changes facilitate the recruitment of certain co-activators through the recognition of a specific motif contained within the co-activator protein.
Prof Malcolm Parker's studies, funded by Cancer Research UK, identified this motif within the co-activator protein known as the LXXLL motif (where L is Leucine and X is any amino acid).
The nuclear receptor family represents a plethora of therapeutic targets for many clinical conditions.
AstraZeneca's research interests initially will focus on the area of respiratory and inflammation; however, broader application is possible across all of the company's research areas.
Targeting the nuclear receptor/co-activator interaction represents an alternative strategy for the inhibition of nuclear receptors.
• Cancer Research UK: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
